Overview
Prevention and Management of Recurrent C. difficile - Expert and Patient Perspectives
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
This activity features two C. difficile patients who discuss their experiences with recurrent C. difficile infection and its impact on their quality of life. Dr. Feuerstadt provides commentary on the patients’ risks for initial and recurrent episodes, recent data, and considerations in the selection of antimicrobial therapy. The discussion also provides insights on improving outcomes and the patient experience.
This activity is intended for ID specialists, gastroenterologists, hospitalists, and other physicians, pharmacists and nurse practitioners who care for patients at risk of C. difficile infection.
Clostridioides difficile infection is associated with significant morbidity, mortality, and impact on patient quality of life. Further, recurrence of C. difficile is common after an initial episode. Although several therapies with varying mechanisms of action are available to treat C. difficile and prevent recurrence, the management of recurrent and refractory C. difficile is complex and challenging. Clinicians require up-to-date knowledge of available guidelines and evidence-based treatment of recurrent C. difficile to reduce its burden and improve clinical outcomes.
Upon completion of this activity, participants will be able to:
• Implement tools to identify patients who may be at increased risk for recurrent C. difficile infection
• Outline evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations
• Describe the role of available antimicrobial agents and biologics for treatment and prevention of recurrent C. difficile infection
• Implement tools to identify patients who may be at increased risk for recurrent C. difficile infection
• Outline evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations
• Describe the role of available antimicrobial agents and biologics for treatment and prevention of recurrent C. difficile infection
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Merck & Company.
Please ensure the computer system you plan to use meets the following minimum requirements:
• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
| I | Patient Case Presentation: Lorraine |
| II | Epidemiology of C. difficile: What Places Patients at-risk? |
| III | Guidelines and Approaches to Reduce Risk in Patients with C. difficile |
| IV | Patient Case Presentation: Melissa |
| V | Prevention of Recurrent C. difficile |
| VI | Gut Microbiome |
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Featuring video commentary from two C. difficile patients, Lorraine and Melissa
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CPE activity.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches under investigation for treating and preventing recurrent C. difficile.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG
Consultant: Ferring Pharmaceuticals, Merck & Company, Roche Diagnostics
Speakers Bureau: Merck & Company
The following have no relevant financial relationships to report:
Lorraine Byrne
Melissa Passarello
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches under investigation for treating and preventing recurrent C. difficile.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katlyn Cooper at kcooper@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.0 contact hour.
ACPE Universal Activity Number: 0396-0000-19-078-H01-P
Activity Type: Knowledge
Release Date: November 8, 2019
Expiration Date: November 8, 2020
Completion of this activity including the pre and post assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
Release Date: November 8, 2019
Expiration Date: November 8, 2020
Completion of this activity including the pre and post assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
